First-line ruxolitinib did not improve complete response in polycythemia vera
Ruxolitinib has long held a defined place in polycythemia vera after hydroxyurea failure or intolerance. The RuxoBEAT trial tested a tougher question: whether moving the JAK inhibitor into first-line treatment could outperform best available therapy in high-risk patients who already needed cytoreduction. It did not. The primary endpoint, clinico-hematologic complete response at 6 months, was essentially flat in both arms, at 2.3% with ruxolitinib and 2.9% with best available therapy.
The result is stark, but it does not close the door on a clinically meaningful role for the drug. Across secondary and exploratory outcomes, ruxolitinib improved several domains that matter at the bedside in polycythemia vera: hematocrit control, splenomegaly, pruritus, and fatigue. In a disease where symptoms, phlebotomy burden, and persistent splenic enlargement can dominate day-to-day care, those gains carry practical weight even when the formal composite response remains rare.
The trial tested a difficult population with real-world treatment needs
RuxoBEAT was a German multicenter open-label phase 2b randomized controlled trial in high-risk polycythemia vera. Eligible patients had to be adults with WHO 2008-defined disease and a clear indication for cytoreduction, such as age over 60 years, prior thrombosis or thromboembolism, extreme thrombocytosis, poor phlebotomy tolerance or frequent phlebotomy requirement, symptomatic or progressive splenomegaly, severe disease-related symptoms, or progressive leukocytosis. Patients could have had only limited prior PV-directed therapy, and the study excluded post-PV myelofibrosis, previous ruxolitinib exposure, inadequate marrow reserve, and several other confounders.
Randomization assigned patients in a 1:1 ratio to ruxolitinib or best available therapy. The starting ruxolitinib dose was 10 mg twice daily, with escalation permitted to 20 mg twice daily. Best available therapy could include hydroxyurea, peginterferon-alpha, other therapy, or no cytoreductive therapy, but combination regimens were not allowed. A crossover option was built into the design: patients in the best-available-therapy arm could switch to ruxolitinib after 6 months if they met criteria for intolerance or resistance.
Baseline characteristics were comparable between groups. The ruxolitinib arm included 44 patients and the best-available-therapy arm 34 patients.
Complete response stayed rare despite biologic activity
The primary endpoint was the clinico-hematologic complete response rate at month 6, a stringent measure combining blood count control with symptom resolution criteria. By that standard, neither strategy came close to producing a robust remission signal. The rates were 2.3% with ruxolitinib and 2.9% with best available therapy, with a p value of 1.000.
The low response rate is important because it shows how hard it is to force a complex myeloproliferative clone into full clinical remission with any single cytoreductive strategy over a short time horizon. Polycythemia vera is driven by chronic marrow overproduction and JAK-STAT signaling, but symptom burden and hematologic control do not always move in lockstep. A therapy can reduce hematocrit, calm splenic congestion, and ease itching without producing the kind of tightly defined composite response that clinical trials use as a primary endpoint.
Symptom control and spleen reduction favored ruxolitinib
Secondary and exploratory analyses pointed in a different direction. Ruxolitinib was significantly more effective than best available therapy in improving hematocrit, splenomegaly, pruritus, and fatigue. Those outcomes reflect the drug’s biological reach beyond simple cell count suppression. JAK inhibition dampens the inflammatory signaling that helps sustain constitutional symptoms and splenic expansion, so the improvement in itching and fatigue fits with the mechanism of action rather than standing apart from it.
A single finding deserves emphasis: ruxolitinib was less effective in reducing platelet counts. In a myeloproliferative disorder where thrombocytosis can be part of the disease phenotype, this differential effect matters because it shows that the drug’s benefits are selective rather than universal. Control of red cell mass and spleen-related disease activity does not guarantee parallel suppression of every myeloid lineage abnormality.
Molecular burden fell in both arms, but treatment persistence favored ruxolitinib
JAK2V617F variant allele frequency decreased significantly from baseline in both groups at 6 months. The trial does not support a claim that first-line ruxolitinib uniquely reduced molecular burden compared with best available therapy over this interval. Instead, the molecular signal appears shared, at least in the short term, across treatment approaches.
The longer view favored ruxolitinib on persistence of therapy. Over the 24-month study period, both time on treatment and duration of treatment were significantly better with ruxolitinib than with best available therapy, with p values below 0.001 and 0.022, respectively. In a chronic disease, sustained treatment exposure often reflects tolerability, symptom relief, and the ability to hold disease control without repeated switches. Patients do not stay on a therapy unless it is doing something useful, and the durability signal here suggests that the clinical advantages of ruxolitinib accumulated beyond the 6-month primary endpoint window.
Safety remained stable without a new signal
No new safety signals emerged. That is particularly relevant because first-line use expands exposure into a population that may not yet have failed conventional therapy. Any move to earlier ruxolitinib would need to justify itself not only on efficacy, but also on confidence that earlier intervention does not create an unexpected toxicity burden. This trial did not reveal one.
The design also included a technical hiccup during randomization: an initial electronic case report form configuration error meant treatment allocation began without the planned stratification and blocking, though allocation concealment remained intact and the problem was corrected in June 2019. The imbalance that resulted was numerical, not the product of investigator selection, and the trial retained its randomized structure.
What the RuxoBEAT result means for first-line practice
RuxoBEAT argues against using ruxolitinib in the hope of achieving a higher formal complete response rate than best available therapy in newly treated high-risk polycythemia vera. The primary endpoint was missed decisively. Yet the trial also shows that the drug can deliver clinically visible benefits where patients often feel them most: spleen size, itching, fatigue, and hematocrit control.
For clinicians, the tension is obvious. A low complete response rate does not erase symptom relief, phlebotomy reduction, or treatment durability. It does, however, limit any claim that first-line ruxolitinib should replace established cytoreductive approaches on the basis of a composite remission endpoint alone. The study leaves open a narrower question: which patients, if any, should be selected early for ruxolitinib because symptom burden or splenic disease outweighs the appeal of conventional first-line cytoreduction. The trial does not answer that directly, and it does not need to. It provides a clearer signal than enthusiasm or habit ever could.